Clinical trials
Large B-cell Lymphoma clinical trials
Below are recruiting large b-cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 392 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05436223RecruitingPhase 2
CD19 CAR-T for certain relapsed or refractory lymphoma
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05442515RecruitingPhase 1/Phase 2
CAR T-cell treatment for hard-to-treat B-cell cancers in youth
This trial tests a personalized immune-cell therapy (CAR T cells) made to attack B-cell cancers that have come back or did not respond to prior treatment. It aims to see how well the treatment works and how safe it is in children and young adults.
Bethesda, MarylandAges 3–39 - NCT05464719RecruitingPhase 2
Loncastuximab for lymphoma patients in partial remission after CAR T
This trial studies loncastuximab tesirine (a targeted cancer medicine) given after CAR T-cell therapy when your lymphoma has improved to a partial remission. It aims to reduce the chance of the lymphoma returning after CAR T.
Houston, TexasAges 18 years+ - NCT05472558RecruitingPhase 1
CAR-NK cell treatment for CD19-positive relapsed lymphoma
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hanzhou, ZhejiangAges 18–75 - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Tucson, ArizonaAges 18 years+ - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT05541341Recruiting
Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Minas Gerais, Belo HorizonteAges birth–100 years - NCT05544019RecruitingPhase 1
Testing an investigational drug for mature B-cell cancers
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
Gilbert, ArizonaAges 18 years+ - NCT05544968RecruitingPhase 1
CD30-targeted cell treatment for hard-to-treat blood cancers
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
Milwaukee, WisconsinAges 18 years+ - NCT05607420RecruitingPhase 1/Phase 2
Testing a new cell therapy for relapsed lymphoma with CD20/CD22
This Phase 1/2 trial studies UCART20x22, a lab-made cell therapy, for people with certain types of relapsed or treatment-resistant B-cell non-Hodgkin lymphoma (NHL). It may help by targeting lymphoma cells that carry CD20 and/or CD22 markers and then testing safety and early effectiveness.
Chicago, IllinoisAges 18–80 - NCT05615636RecruitingPhase 2
Study of four medicines for relapsed B-cell lymphoma
This Phase 2 trial tests a combination of several medicines for people whose lymphoma has come back or did not respond to prior treatment. It aims to shrink the lymphoma by using different ways to attack B-cell cancer.
Houston, TexasAges 18 years+ - NCT05633615RecruitingPhase 2
Testing new drug options after CAR T for aggressive lymphoma
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
Tucson, ArizonaAges 18 years+ - NCT05641428RecruitingPhase 2
Testing a made-at-bedside CAR T cell for relapsed lymphoma
This Phase 2 study compares a “point-of-care” CAR T-cell treatment made at the hospital right away versus standard commercial CAR T-cells. It’s for adults with relapsed or refractory large B-cell lymphoma (a type of blood cancer) to see which approach works best and is safe.
AmsterdamAges 18 years+ - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT05648019RecruitingPhase 2
CD19 CAR T-cell therapy for tough B-cell blood cancers
This Phase 2 study tests a one-time CAR T-cell treatment aimed at CD19, a target found on many B-cell leukemias and lymphomas. It’s for people whose disease has come back or hasn’t responded to prior treatments, or who can’t have a stem cell transplant.
SingaporeAges birth–70 years - NCT05659628RecruitingPhase 1
CD19 CAR-T plus PD-1 antibody for relapsed lymphoma
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
Hangzhou, ZhejiangAges 18–75 - NCT05702853RecruitingPhase 1/Phase 2
CAR T-cell therapy after CD34 selection for CD19 lymphoma or CLL
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
Charleston, South CarolinaAges 18 years+ - NCT05757219RecruitingPhase 2
Itacitinib before CAR T for aggressive B-cell lymphoma
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Tampa, FloridaAges 18 years+ - NCT05780034RecruitingPhase 1
Study drug AC676 for certain relapsed blood cancers
This Phase 1 trial tests AC676, a study medicine, for adults with certain B-cell blood cancers that have come back or did not respond to prior treatment. It may help people who have tried standard therapies and need new options.
Denver, ColoradoAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Miami, FloridaAges 18 years+ - NCT05800405RecruitingEarly Phase 1
Radiation before CAR T therapy for large B-cell lymphoma
This early-phase study tests whether giving targeted radiation first can improve outcomes when you later receive CAR T-cell therapy for large B-cell lymphoma that has come back or is not responding to treatment. It may help shrink or control lymphoma spots before CAR T is infused.
Duarte, CaliforniaAges 18 years+ - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+ - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Irvine, CaliforniaAges 18 years+
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for large b-cell lymphoma?
- Yes. Clin2 currently lists 392 recruiting large b-cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a large b-cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a large b-cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma (PMBCL)
- Refractory Primary Mediastinal Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.